This technology is a combinatorial treatment to target tumors harboring genetic alterations of the tumor suppressor gene Leucine Zipper-like Transcription Regulator 1 (LZTR1).
This technology is a multiplex immunofluorescence method using beam-splitting imaging and non-specific antibodies to create a high-throughput, efficient approach for cell type identification.